InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: trading.jeff post# 38008

Friday, 01/20/2017 1:41:22 PM

Friday, January 20, 2017 1:41:22 PM

Post# of 48316
Merck CEO sees Keytruda in pole position in cancer race
http://reut.rs/2iNX86R

Chief Executive Ken Frazier said that Keytruda in combination therapy could also be cheaper than some rival approaches -- an increasingly important consideration in an era of heightened controversy about high drug prices.


MRK is doing a lot of combo trials and he isn't talking about ONCS combo by any means. However, he recognizes the importance of combo trials that could offer cost benefits for sure and ONCS combo could provide some, in melanoma at least.